Resources Resource Type All Resources Poster (10) Presentation (5) Publication (27) Year All Years 2025 (4) 2024 (6) 2023 (6) 2022 (2) 2021 (5) 2020 (4) 2019 (1) 2018 (3) 2014 (3) 2011 (3) 2009 (1) 2007 (1) 2006 (1) 2005 (2) Search Found 42 Results January 4, 2024 A phase 2 trial of CD24Fc for prevention of graft-versus-host disease Read more November 1, 2023 Single agent Safety and Activities of Target preserving Anti CTLA 4 Antibody Gotistobart (ONC 392/BNT316) in PD –(L)1 Resistant Metastatic NSCLC and Population PK Analysis in Patients with Solid Tumors Read more September 22, 2023 Preserving CTLA-4 Checkpoint Function for Safer and More effective Immunotherapy Read more September 14, 2023 Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4– and PD-1–targeted immunotherapy Read more May 10, 2023 Safety and Clinical Activity of Target Preserving Anti-CTLA-4 Antibody ONC-392/BNT316 as Monotherapy in NSCLC Patients who Progressed on PD-(L)1 targeting Immunotherapy Read more May 10, 2023 PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 /BNT316 Versus Docetaxel in Metastatic Non-Small Cell LungCancers that Progressed on PD-1/PD-L1 Inhibitors (NCT05671510) Read more «12345»
